Pao Pereira potentialise les effets du carboplatine contre le cancer de l'ovaire

Titre de la Publication: "L'extrait végétal de Pao Pereira potentialise les effets du carboplatine contre le cancer de l'ovaire."

Publié dans " Informa Healthcare "

Jun Yu, PhD, Qi Chen, PhD.  – ISSN 1388-0209 print/ISSN 1744-5116 –
Pharmaceutical Biology

Des recherches récentes menées au centre médical de l'université du Kansas montrent qu'une préparation à base de plantes de Pao pereira, fournie par Natural Source International, Ltd. pourrait être extrêmement utile. Elle conclut que "In vivo, Pao pereira seul a supprimé la croissance de la tumeur de 79% et a diminué le volume de l'ascite de 55%. Lorsque le Pao pereira a été associé au carboplatine, l'inhibition de la tumeur a atteint 97 % et l'ascite a été complètement éradiquée. Pao pereira possède une puissante activité antitumorale et pourrait renforcer l'effet du carboplatine. Il présente donc un potentiel thérapeutique dans le traitement du cancer de l'ovaire."

Il s'agit d'une étude révolutionnaire si l'on considère que l'American Cancer Society estime qu'en 2013, environ 22 240 nouveaux cas de cancer de l'ovaire seront diagnostiqués et que 14 030 femmes mourront de ce cancer aux États-Unis. Selon les données, les taux de mortalité liés au cancer de l'ovaire ne se sont pas améliorés au cours des quarante années qui ont suivi la déclaration de la "guerre contre le cancer".

La préparation à base de plantes de Pao pereira est utilisée depuis longtemps par les patients et les praticiens de la médecine intégrative en Amérique du Sud. Cette étude porte sur les effets anticancéreux du Pao pereira (Pao), seul ou en combinaison avec des médicaments de chimiothérapie (carboplatine), dans des modèles précliniques de cancer de l'ovaire.

Les résultats de l'étude constituent une percée dans la recherche sur le cancer de l'ovaire!

Le Pao pereira a inhibé de manière sélective la croissance des cellules cancéreuses de l'ovaire et a induit l'apoptose (mort cellulaire programmée). Le Pao pereira a également considérablement augmenté la cytotoxicité des médicaments de chimiothérapie.

In vivo, Pao pereira seul a supprimé la croissance de la tumeur de 79% et a diminué le volume de l'ascite de 55%. Lorsque Pao pereira a été associé à la chimiothérapie, l'inhibition de la tumeur a atteint 97 % et l'ascite a été complètement éradiquée.
Les chercheurs concluent que le Pao Pereira a un potentiel thérapeutique dans le traitement du cancer de l'ovaire.

Résumé de la Publication

La préparation à base de plantes de Pao pereira [Geissospermum vellosii Allem (Apocynaceae)] est utilisée depuis longtemps par les patients en oncologie et les praticiens de la médecine intégrative en Amérique du Sud. Cependant, ses activités anticancéreuses n'ont pas été systématiquement étudiées. Objectif : Étudier les effets anticancéreux de l'extrait enrichi en alcaloïdes b-carboliniques de Pao pereira (Pao), seul ou en combinaison avec du carboplatine, dans des modèles précliniques de cancer de l'ovaire. Matériaux et méthodes : La cytotoxicité du Pao (0-800 mg/ml) contre différentes lignées cellulaires de cancer ovarien et une lignée de cellules épithéliales immortalisées a été détectée par cytométrie en flux, test MTT et formation de colonies dans de la gélose molle. La combinaison de Pao et de carboplatine, un médicament chimiothérapeutique primaire pour le cancer de l'ovaire, a été évaluée en utilisant les méthodes de Chou-Talalay. Des souris porteuses d'un cancer de l'ovaire induit par voie intrapéritonéale ont été traitées par 20 ou 50 mg/kg/jour de Pao par injection i.p.. Le carboplatine à 15 mg/kg/semaine par voie i.p. a été comparé et associé aux traitements par Pao. Résultats : Le Pao a inhibé sélectivement la croissance des cellules cancéreuses ovariennes avec des valeurs IC50 de 180-235 mg/ml, comparées à 537 mg/ml dans les cellules normales. Le Pao a induit l'apoptose en fonction de la dose et du temps et a complètement inhibé la formation de colonies de cellules tumorales dans la gélose molle à 400 mg/ml. Le Pao a considérablement augmenté la cytotoxicité du carboplatine, avec des réductions de dose (DRI) pour le carboplatine de 1,2 à 10 fois. In vivo, le Pao seul a supprimé la croissance tumorale de 79 % et a diminué le volume de l'ascite de 55 %. Lorsque Pao a été associé au carboplatine, l'inhibition de la tumeur a atteint 97 % et l'ascite a été complètement éradiquée. Discussion et conclusion : le Pao possède une puissante activité antitumorale et peut renforcer l'effet du carboplatine: il présente donc un potentiel thérapeutique dans le traitement du cancer de l'ovaire.


Des recherches menées au centre médical de l’Université du Kansas sur l’effet des extraits de plantes sur le cancer de l’ovaire concluent que « In vivo, Pao pereira (Pau pereira) à lui seul a supprimé la croissance tumorale de 79% et diminué le volume d’ascite de 55%. Lorsque Pao pereira (Pau pereira) a été associé au carboplatine, l’inhibition de la tumeur a atteint 97% et l’ascite a été complètement éradiquée. Pao pereira (Pau pereira) possède une puissante activité antitumorale et travaille en synergie avec la chimiothérapie ».

133 – The anticancer Agent PB-100, Selectively Active on Malignant Cells, Inhibits Multiplication of 16 Malignant Cell Lines, even Multidrug Resistant

Genetics and Molecular Biology 2000, vol 23 nº1, pp. 29.

Available in English only

ABSTRACT IN ENGLISH: The plant-derived anticancer agent PB-100 (Beljanski® Pao extract) selectively destroys cancer cells, even when multidrug resistant; yet, it does not inhibit normal (non-malignant) cell multiplication. Testing of PB-100 on sixteen cell lines, several multidrug resistant, as well as on five normal cell lines, confirmed our previous results. Flavopereirine and dihydroflavopereirine, the active principles of PB-100, were chemically synthesized and displayed the same selectivity for tumor cells as the purified plant extract, being active at even lower concentrations.

List of cell lines tested : brain (4), ovary (2), breast (2), prostate thyroid (2), colon (2), pancreatic, hepatic, kidney, skin, liver

ABSTRACT IN PORTUGUES : O agente anticancerigeno de origem vegetal PB-100 destroi seletivamente as células cancerosas, mesmo quando elas sao resistentes a multiplas drogas; no entanto, ele nao inibe a multiplicacao de células normais (nao malignas). O teste do PB-100 em 16 linhagens de células malignas, assim como em 5 linhagens de células normais, confirmou nosso resultados prévios. Flavopereirine e dihidroflavopereirine, os principios ativos do PB-100, foram sintetizados quimicamente e mostraram a mesma seletividade para as células tumorais que o extrato purificado da planta, sendo ativos em concentraçoes ainda menores.


ABSTRACT IN ENGLISH: The plant-derived anticancer agent PB-100 (Beljanski® Pao extract) selectively destroys cancer cells, even when multidrug resistant; yet, it does not inhibit normal (non-malignant) cell multiplication. Testing of PB-100 on sixteen cell lines, several multidrug resistant, as well as on five normal cell lines, confirmed our previous results. Flavopereirine and dihydroflavopereirine, the active principles of PB-100, were chemically synthesized and displayed the same selectivity for tumor cells as the purified plant extract, being active at even lower concentrations.

List of cell lines tested : brain (4), ovary (2), breast (2), prostate thyroid (2), colon (2), pancreatic, hepatic, kidney, skin, liver

ABSTRACT IN PORTUGUES : O agente anticancerigeno de origem vegetal PB-100 destroi seletivamente as células cancerosas, mesmo quando elas sao resistentes a multiplas drogas; no entanto, ele nao inibe a multiplicacao de células normais (nao malignas). O teste do PB-100 em 16 linhagens de células malignas, assim como em 5 linhagens de células normais, confirmou nosso resultados prévios. Flavopereirine e dihidroflavopereirine, os principios ativos do PB-100, foram sintetizados quimicamente e mostraram a mesma seletividade para as células tumorais que o extrato purificado da planta, sendo ativos em concentraçoes ainda menores.

131 – Mitogenic Effect of Several Interleukins, Neuromediators and Hormones on Human Glioblastoma Cells, and its Inhibition by the Selective Anticancer Agent PB-100

Deutsche Zeitschrift für Onkologie, 28, 1, 1996, pp. 14-22

Available in English only

ABSTRACT: We investigated in vitro the effect of six different substances present in the brain on two human cell lines: U251-BCNU-resistant glioblastoma cells, derived from a highly malignant cerebral tumor, and, as their normal counterparts, CRL 1656 astrocytes. The cytokines IL-4 and IL-10 (alone or together with IL-6), the catecholamine neuromediators dopamine and epinephrine, the steroid hormones progesterone and testosterone all significantly stimulated multiplication of the glioblastoma cells, but enhanced to a much lesses extent multiplication of normal astrocytes. The selective anticancer agent PB-100* inhibited these stimulatory effects. In addition, it could dose-dependently kill over 98% of the malignant cells while not affecting normal cells.


ABSTRACT: We investigated in vitro the effect of six different substances present in the brain on two human cell lines: U251-BCNU-resistant glioblastoma cells, derived from a highly malignant cerebral tumor, and, as their normal counterparts, CRL 1656 astrocytes. The cytokines IL-4 and IL-10 (alone or together with IL-6), the catecholamine neuromediators dopamine and epinephrine, the steroid hormones progesterone and testosterone all significantly stimulated multiplication of the glioblastoma cells, but enhanced to a much lesses extent multiplication of normal astrocytes. The selective anticancer agent PB-100* inhibited these stimulatory effects. In addition, it could dose-dependently kill over 98% of the malignant cells while not affecting normal cells.

130 – The selective anticancer agents PB-100 and BG-8 are active against human melanoma cells, but do not affect non malignant fibroblasts

International Journal of Oncology 8:1143-1148, 1996

Available in English only

ABSTRACT: When past the stage amenable to surgery, melanoma and its metastases are, as a rule, treated with chemotherapy, which is largely unsuccessful. In this report, experimental evidence is presented demonstrating that, in vitro, two selective anticancer agents, PB-100 and BG-8, dose dependently destroy human G-361 melanoma cells, but do not affect human non malignant CCD-974Sk fibroblasts used as controls. Trace metal compounds, present, often in abnormal amounts, in the cancer cell and/or its environment, are known to influence its proliferation. Assays were carried out using highly elevated amounts of ferritin, iron chloride or zinc chloride. Ferritin proved differentially mitogenic for melanoma cells and fibroblasts. Its activity was inhibited by both anticancer agents, which however tended to become less efficacious in its presence. FeCl3 was more moderately, but equally, mitogenic for malignant and normal cells, yet it impaired antiproliferative activity of PB-100 and inhibited that of BG-8. ZnCl2 exhibited a selective antiproliferative activity on the malignant melanoma cells; it did not compete with PB-100 or BG-8. Specific recognition and destruction of malignant cells by the two anticancer agents are discussed.


ABSTRACT: When past the stage amenable to surgery, melanoma and its metastases are, as a rule, treated with chemotherapy, which is largely unsuccessful. In this report, experimental evidence is presented demonstrating that, in vitro, two selective anticancer agents, PB-100 and BG-8, dose dependently destroy human G-361 melanoma cells, but do not affect human non malignant CCD-974Sk fibroblasts used as controls. Trace metal compounds, present, often in abnormal amounts, in the cancer cell and/or its environment, are known to influence its proliferation. Assays were carried out using highly elevated amounts of ferritin, iron chloride or zinc chloride. Ferritin proved differentially mitogenic for melanoma cells and fibroblasts. Its activity was inhibited by both anticancer agents, which however tended to become less efficacious in its presence. FeCl3 was more moderately, but equally, mitogenic for malignant and normal cells, yet it impaired antiproliferative activity of PB-100 and inhibited that of BG-8. ZnCl2 exhibited a selective antiproliferative activity on the malignant melanoma cells; it did not compete with PB-100 or BG-8. Specific recognition and destruction of malignant cells by the two anticancer agents are discussed.

128 – The anticancer agent PB-100 concentrates in the nucleus and nucleoli of human glioblastoma cells but does not enter normal astrocytes

International Journal of Oncology 7:81-85, 1995.

Available in English only

ABSTRACT: Selectivity of the anticancer agent PB-100 for malignant cells, already demonstrated using cell growth and viability evaluation, is now confirmed by microscopic observations. PB-100 is easily detected inside cells by its yellow color under visible light and by its blue fluorescence; it may be measured in isolated nuclei using its characteristic UV absorbance. After short treatment of human BCNU-resistant glioblastoma cells (U 251) and normal astrocyte controls (CRL 1656), PB-100 accumulates in the malignant cell nucleus, particularly concentrating in the multiple nucleoli and rapidly inducing glioblastoma cell death, whilst, in contrast, the anticancer agent does not even enter normal cells. We had already shown that PB-100 binds to DNA of cancer cells, but not to that of normal cells. In vitro tests described in this report indicate that PB-100 binds to purine bases, but not to pyrimidines, of various ribopolymers and its binding to purine rich nucleic acid stretches is inferred.


ABSTRACT: Selectivity of the anticancer agent PB-100 for malignant cells, already demonstrated using cell growth and viability evaluation, is now confirmed by microscopic observations. PB-100 is easily detected inside cells by its yellow color under visible light and by its blue fluorescence; it may be measured in isolated nuclei using its characteristic UV absorbance. After short treatment of human BCNU-resistant glioblastoma cells (U 251) and normal astrocyte controls (CRL 1656), PB-100 accumulates in the malignant cell nucleus, particularly concentrating in the multiple nucleoli and rapidly inducing glioblastoma cell death, whilst, in contrast, the anticancer agent does not even enter normal cells. We had already shown that PB-100 binds to DNA of cancer cells, but not to that of normal cells. In vitro tests described in this report indicate that PB-100 binds to purine bases, but not to pyrimidines, of various ribopolymers and its binding to purine rich nucleic acid stretches is inferred.

126 – Selective inhibitor (PB-100) of human glioblastoma cell multiplication

International Journal of Oncology, 5:873-879, 1994.

Available in English. French version available on request.

ABSTRACT: The multifunctional cytokine interleukin-6 behaves as a growth factor for various malignancies. It is produced in significant amounts by glioblastoma cells. When exogenous IL-6 is added (pg/ml) to culture medium of human glioblastoma cells and normal (non malignant) astrocytes used as controls, it exerts a dose dependent and differential effect on these two cell lines. Enhancement of cell proliferation is twice as high for glioblastoma cells as for astrocytes. In vitro, the novel anticancer agent PB-100 (mu g/ml) dose dependently inhibits this stimulatory activity. In addition, increasing PB-100 concentrations finally induce death of the malignant cells, yet do not impede multiplication of normal astrocytes. PB-100 does not abolish IL-6 production by cells, but keeps its level down to physiological values. PB-100 should therefore find its place in therapies requiring control of IL-6 production.


ABSTRACT: The multifunctional cytokine interleukin-6 behaves as a growth factor for various malignancies. It is produced in significant amounts by glioblastoma cells. When exogenous IL-6 is added (pg/ml) to culture medium of human glioblastoma cells and normal (non malignant) astrocytes used as controls, it exerts a dose dependent and differential effect on these two cell lines. Enhancement of cell proliferation is twice as high for glioblastoma cells as for astrocytes. In vitro, the novel anticancer agent PB-100 (mu g/ml) dose dependently inhibits this stimulatory activity. In addition, increasing PB-100 concentrations finally induce death of the malignant cells, yet do not impede multiplication of normal astrocytes. PB-100 does not abolish IL-6 production by cells, but keeps its level down to physiological values. PB-100 should therefore find its place in therapies requiring control of IL-6 production.

125 – The selective anticancer agent PB-100 inhibits interleukin-6 induced enhancement of glioblastoma cell in vitro

International Journal of Oncology, 5:873-879, 1994.

Available online in English. French version upon request.

ABSTRACT: The multifunctional cytokine interleukin-6 behaves as a growth factor for various malignancies. It is produced in significant amounts by glioblastoma cells. When exogenous IL-6 is added (pg/ml) to culture medium of human glioblastoma cells and normal (non malignant) astrocytes used as controls, it exerts a dose dependent and differential effect on these two cell lines. Enhancement of cell proliferation is twice as high for glioblastoma cells as for astrocytes. In vitro, the novel anticancer agent PB-100 (mu g/ml) dose dependently inhibits this stimulatory activity. In addition, increasing PB-100 concentrations finally induce death of the malignant cells, yet do not impede multiplication of normal astrocytes. PB-100 does not abolish IL-6 production by cells, but keeps its level down to physiological values. PB-100 should therefore find its place in therapies requiring control of IL-6 production.


ABSTRACT: The multifunctional cytokine interleukin-6 behaves as a growth factor for various malignancies. It is produced in significant amounts by glioblastoma cells. When exogenous IL-6 is added (pg/ml) to culture medium of human glioblastoma cells and normal (non malignant) astrocytes used as controls, it exerts a dose dependent and differential effect on these two cell lines. Enhancement of cell proliferation is twice as high for glioblastoma cells as for astrocytes. In vitro, the novel anticancer agent PB-100 (mu g/ml) dose dependently inhibits this stimulatory activity. In addition, increasing PB-100 concentrations finally induce death of the malignant cells, yet do not impede multiplication of normal astrocytes. PB-100 does not abolish IL-6 production by cells, but keeps its level down to physiological values. PB-100 should therefore find its place in therapies requiring control of IL-6 production.

123 – Le PB100 : Inhibiteur sélectif puissant de la multiplication des cellules de glioblastome humain résistantes au BCNU

Anticancer Research, vol.13, n°6A, Nov. Dec. 1993, pp. 2301-2308.

Available online in French, summary in English

ABSTRACT: Major drawbacks to present-day cancer chemotherapy are its intrinsic lack of selectivity for tumour cells, resulting in severe damage to normal rapidly dividing cells, and the widespread emergence of drug resistance. Here experimental evidence is presented demonstrating that PB-100, a beta-carboline alkaloid, selectively inhibits in vitro multiplication of human BCNU-resistant glioblastoma cells (U251), but has no effect on normal astrocyte (CRL 1656) multiplication. PB-100 activity is dose-dependent. In the presence of ferritin or CaCl2, which are highly mitogenic for glioblastoma cells, higher doses of the alkaloid are required to inhibit multiplication completely. PB-100 is one of several compounds which were selected for their specific action on cancer DNA and cells, together with lack of activity on normal DNA and cells. Both the selectivity of PB-100 and its ability to overcome drug resistance stem from its effect on cancer DNA secondary structure. This activity is described and discussed, and therapeutic applications are mentioned..


ABSTRACT: Major drawbacks to present-day cancer chemotherapy are its intrinsic lack of selectivity for tumour cells, resulting in severe damage to normal rapidly dividing cells, and the widespread emergence of drug resistance. Here experimental evidence is presented demonstrating that PB-100, a beta-carboline alkaloid, selectively inhibits in vitro multiplication of human BCNU-resistant glioblastoma cells (U251), but has no effect on normal astrocyte (CRL 1656) multiplication. PB-100 activity is dose-dependent. In the presence of ferritin or CaCl2, which are highly mitogenic for glioblastoma cells, higher doses of the alkaloid are required to inhibit multiplication completely. PB-100 is one of several compounds which were selected for their specific action on cancer DNA and cells, together with lack of activity on normal DNA and cells. Both the selectivity of PB-100 and its ability to overcome drug resistance stem from its effect on cancer DNA secondary structure. This activity is described and discussed, and therapeutic applications are mentioned..